By Hendra Lukman 
Stanford Medicine researchers have achieved a significant milestone in the fight against Type 1 diabetes, demonstrating in mice that a combination of blood-forming stem cells and pancreatic islet cells from an immunologically mismatched donor can completely prevent or fully reverse the disease. This groundbreaking approach establishes a hybrid immune system within the recipient, effectively halting the autoimmune assault that characterizes Type 1 diabetes and eliminating the need for immunosuppressive drugs or insulin in the treated animals for the duration of a six-month study. The findings, published online November 18 in the Journal of Clinical Investigation, offer a beacon of hope for millions worldwide affected by this chronic condition and potentially other autoimmune disorders.
The Challenge of Autoimmunity: A New Paradigm for Diabetes Treatment
Type 1 diabetes is a devastating autoimmune disease where the body’s own immune system mistakenly identifies insulin-producing beta cells in the pancreas as foreign invaders and systematically destroys them. This loss of insulin-producing capacity leads to severe hyperglycemia, requiring lifelong insulin therapy and posing a significant risk of debilitating long-term complications affecting the eyes, kidneys, nerves, and cardiovascular system.
Previous research, including a pivotal 2022 study by the same Stanford team, had focused on restoring blood sugar control by transplanting islet cells into mice where diabetes was experimentally induced through toxin-induced cell destruction. While successful, this approach primarily addressed the challenge of immune rejection of donor cells. The latest study, however, tackles a far more complex scenario: Type 1 diabetes driven by endogenous autoimmunity, mirroring the human disease. In this context, transplanted islets face a dual threat: they are recognized as foreign, and the recipient’s immune system is already pre-programmed to attack islet cells, regardless of their origin.
"Just like in human Type 1 diabetes, the diabetes that occurs in these mice results from an immune system that spontaneously attacks the insulin-producing beta cells in pancreatic islets," explained Seung K. Kim, MD, PhD, the KM Mulberry Professor and a professor of developmental biology, gerontology, endocrinology and metabolism at Stanford Medicine. "We need to not only replace the islets that have been lost but also reset the recipient’s immune system to prevent ongoing islet cell destruction. Creating a hybrid immune system accomplishes both goals."
A Refined Protocol: The Power of a Hybrid Immune System
The key to the Stanford team’s success lies in the creation of a hybrid immune system. This is achieved through a carefully orchestrated transplantation of both blood-forming stem cells and pancreatic islet cells from an immunologically mismatched donor. The blood-forming stem cells, when engrafted, begin to generate a new immune system that is a mosaic of both donor and recipient cells. This hybrid system is crucial because it learns to tolerate the donor islet cells while simultaneously ceasing its attack on the recipient’s own remaining healthy tissues.
A significant hurdle in adapting this approach for autoimmune diseases is that the very biological mechanisms driving autoimmunity can also make the recipient’s system more resistant to the conditioning required for blood stem cell transplantation. The Stanford team ingeniously navigated this challenge by incorporating a medication commonly used to treat autoimmune diseases into their pre-transplant regimen. This simple yet critical modification to the 2022 protocol proved to be the missing piece.
In the latest study, when this adjusted protocol was applied, followed by the combined transplantation of blood stem cells and islet cells from an unrelated donor, the results were striking. In 19 out of 19 mice, the combined transplant led to the development of a hybrid immune system, and crucially, these animals did not develop Type 1 diabetes. Even more remarkably, in a separate cohort of mice that already had long-standing Type 1 diabetes, nine out of nine were completely cured after receiving the combined transplant. This indicates not only preventative capabilities but also a potent reversal effect on established disease.
"None of the animals developed graft-versus-host disease (GVHD), a condition in which the immune system arising from the donated blood stem cells attacks healthy tissue in the recipient," stated Dr. Kim. "This is a critical observation, as GVHD has been a significant concern in stem cell transplantation. Furthermore, the destruction of islet cells by the animals’ original immune system came to a stop. After receiving the transplants, the mice no longer needed immune suppressive drugs or insulin at any point during the six-month study."
Building on a Legacy: From Kidney Tolerance to Diabetes Reversal
This pioneering work stands on the shoulders of decades of research into immune tolerance and stem cell transplantation. The concept of a hybrid immune system was significantly advanced by the late Samuel Strober, MD, PhD, a renowned professor of immunology and rheumatology at Stanford, and his colleagues, including study co-author Judith Shizuru, MD, PhD, a professor of medicine. Their earlier research demonstrated that bone marrow transplants from partially matched human donors could induce a hybrid immune system in recipients, leading to long-term acceptance of kidney transplants from the same donor, often without the need for continuous immunosuppressive drugs. This paved the way for understanding how to create immune tolerance to foreign tissues.
"Based on many years of basic research by us and others, we know that blood stem cell transplants could also be beneficial for a wide range of autoimmune diseases," said Dr. Shizuru. "The challenge has been to devise a more benign pre-treatment process, diminishing risk to the point that patients suffering from an autoimmune deficiency that may not be immediately life-threatening would feel comfortable undergoing the treatment."
Traditionally, blood stem cell transplants, primarily used for blood cancers like leukemia and lymphoma, necessitate high-dose chemotherapy and radiation to eradicate the patient’s existing immune system. This intensive conditioning, while effective for cancer, carries substantial risks and severe side effects. Dr. Shizuru and her team have been instrumental in developing a gentler, less toxic approach for preparing individuals with non-cancerous conditions for blood stem cell transplantation. This modified conditioning aims to reduce bone marrow activity just enough to allow donor stem cells to engraft and flourish, minimizing collateral damage to healthy tissues.
"Now we know that the donated blood stem cells re-educate the recipient animal’s immune system to not only accept the donated islets, but also not attack its healthy tissues, including islets," Dr. Kim emphasized. "In turn, the donated blood stem cells and the immune system they produce learn to not attack the recipient’s tissues, and graft-versus-host disease can be avoided."
The Path Forward: Translating Mouse Success to Human Trials
The implications of these findings are profound, and the researchers are optimistic about their potential translation to human therapies. The pre-transplant conditioning regimen used in the mice—involving specific antibodies, drugs, and low-dose radiation—is already part of standard clinical practice for blood stem cell transplantation. This familiarity with the components of the protocol significantly streamlines the pathway toward human clinical trials.
"The possibility of translating these findings into humans is very exciting," stated Dr. Kim. "The key steps in our study — which result in animals with a hybrid immune system containing cells from both the donor and the recipient — are already being used in the clinic for other conditions. We believe this approach will be transformative for people with Type 1 diabetes or other autoimmune diseases, as well as for those who need solid organ transplants."
The research was led by Preksha Bhagchandani, a graduate and medical student at Stanford, with significant contributions from Stephan Ramos, PhD, a postdoctoral fellow and co-author. Dr. Kim serves as the senior author, directing the Stanford Diabetes Research Center and the Northern California Breakthrough T1D Center of Excellence.
Overcoming Future Hurdles: Sourcing and Scale
Despite the remarkable success in the mouse models, several significant obstacles must be addressed before this strategy can be widely implemented in humans. A primary challenge is the current reliance on pancreatic islets obtained from deceased donors. Furthermore, the blood stem cells and islet cells must originate from the same individual donor. The availability of suitable donors who can provide both components in sufficient quantities for transplantation remains a logistical and ethical consideration.
Another crucial question is whether the number of islet cells typically recovered from a single deceased donor would be adequate to reverse established Type 1 diabetes in human patients, especially those with more advanced disease. The researchers are actively exploring innovative solutions to these limitations. One promising avenue involves the laboratory cultivation of large quantities of functional islet cells from pluripotent human stem cells. Simultaneously, efforts are underway to develop methods that enhance the survival and efficiency of transplanted donor islets post-transplantation.
Broader Horizons: Beyond Diabetes
The potential applications of this gentle pre-conditioning strategy extend far beyond Type 1 diabetes. The Stanford team believes that this approach could unlock the door to stem cell transplants for a wide spectrum of autoimmune diseases, including rheumatoid arthritis and lupus. It also holds promise for treating non-cancerous blood disorders like sickle cell anemia, where current blood stem cell transplant methods are still considered harsh. Moreover, the ability to create immune tolerance could revolutionize solid organ transplantation, allowing for the use of mismatched organs and potentially expanding the donor pool significantly.
"The ability to reset the immune system safely to permit durable organ replacement could rapidly lead to great medical advances," Dr. Kim concluded.
The research was generously supported by grants from the National Institutes of Health (NIH), the Breakthrough T1D Northern California Center of Excellence, Stanford Bio-X, the Reid Family, the H.L. Snyder Foundation and Elser Trust, the VPUE Research Fellowship at Stanford, and the Stanford Diabetes Research Center. This multi-faceted support underscores the collaborative and resource-intensive nature of such transformative scientific endeavors.
